1. Azole antifungal agents (fluconazole, itraconazole, voriconazole) share a common mechanism of action. Which enzyme is the primary target of the azole class?
A) Glucan synthase, the enzyme that polymerizes UDP-glucose into beta-1,3-glucan chains in the fungal cell wall
B) CYP51 (lanosterol 14-alpha-demethylase), the fungal cytochrome P450 enzyme that converts lanosterol to ergosterol precursors
C) Thymidylate synthase, a folate-cycle enzyme required for fungal DNA synthesis
D) Chitin synthase, the enzyme that incorporates N-acetylglucosamine into the structural chitin layer of the fungal cell wall
E) Squalene epoxidase, the enzyme that converts squalene to squalene epoxide early in the sterol biosynthesis pathway
ANSWER: B
Rationale:
Option B is correct. Azole antifungals inhibit CYP51, the fungal cytochrome P450 enzyme also called lanosterol 14-alpha-demethylase, which catalyzes the removal of the 14-alpha-methyl group from lanosterol during ergosterol biosynthesis. Ergosterol is the primary sterol in the fungal cell membrane, serving the structural and functional role that cholesterol serves in mammalian membranes. Azole inhibition of CYP51 depletes ergosterol and causes accumulation of 14-alpha-methylated sterol intermediates that disrupt membrane integrity, fluidity, and the function of membrane-embedded proteins. The azole triazole nitrogen coordinates with the heme iron of CYP51, blocking substrate access.
Option A: Option A is incorrect because glucan synthase is the target of echinocandins (caspofungin, micafungin, anidulafungin), not azoles.
Option C: Option C is incorrect because thymidylate synthase is not the target of any clinically used antifungal agent; 5-fluorocytosine (flucytosine) inhibits thymidylate synthase after intracellular conversion to 5-fluorouracil, but flucytosine is not an azole.
Option D: Option D is incorrect because chitin synthase inhibition is not the mechanism of any approved antifungal drug class.
Option E: Option E is incorrect because squalene epoxidase is the target of allylamines (terbinafine, naftifine), not azoles; allylamine inhibition blocks an earlier step in sterol synthesis than azoles do.
2. A hospitalized patient with esophageal candidiasis is being switched from intravenous to oral fluconazole. The treating team is confident that oral dosing will achieve equivalent drug exposure. Which pharmacokinetic property of fluconazole best justifies this clinical decision?
A) Fluconazole undergoes extensive first-pass hepatic metabolism that reduces oral bioavailability to approximately 50%, requiring a dose increase when switching from IV to oral
B) Fluconazole is highly lipophilic with a large volume of distribution, ensuring high tissue concentrations regardless of the route of administration
C) Fluconazole is actively transported across the intestinal epithelium by OATP (organic anion transporting polypeptide) carriers, giving it route-independent plasma concentrations
D) Fluconazole has an oral bioavailability of approximately 90% that is not significantly affected by food, gastric pH, or acid-suppressing medications
E) Fluconazole is a prodrug that requires gastric acid hydrolysis to release the active triazole moiety, making oral and IV formulations pharmacologically equivalent only at low gastric pH
ANSWER: D
Rationale:
Option D is correct. Fluconazole has oral bioavailability of approximately 90%, one of the highest among systemic antifungal agents. This near-complete absorption is not dependent on gastric acid, food intake, or the presence of bile acids, making IV-to-oral conversion straightforward at the same dose with no adjustment required. This property makes fluconazole unusual among antifungals and gives it a substantial practical advantage over itraconazole capsules, whose absorption is highly pH- and food-dependent.
Option A: Option A is incorrect; fluconazole does not undergo significant first-pass metabolism and its oral bioavailability is approximately 90%, not 50%. There is no dose increase required when switching from IV to oral fluconazole.
Option B: Option B is incorrect; fluconazole is actually relatively hydrophilic compared to other azoles, with a small-to-moderate volume of distribution (approximately 0.7 L/kg), and its suitability for IV-to-oral conversion is based on its high bioavailability, not tissue accumulation.
Option C: Option C is incorrect; fluconazole absorption is primarily passive and is not dependent on active OATP transport.
Option E: Option E is incorrect; fluconazole is not a prodrug. It is active as administered and does not require acid-mediated activation.
3. A patient with blastomycosis is prescribed itraconazole capsules. She also takes omeprazole (a proton pump inhibitor) daily for gastroesophageal reflux. Which statement best describes how her omeprazole use will affect itraconazole capsule absorption?
A) Omeprazole raises gastric pH, impairing dissolution of itraconazole capsules and dramatically reducing oral bioavailability, sometimes to near zero
B) Omeprazole has no clinically meaningful effect on itraconazole capsule absorption because itraconazole dissolves independently of gastric acid
C) Omeprazole inhibits CYP3A4 in the gut wall, increasing itraconazole bioavailability by reducing first-pass metabolism
D) Omeprazole accelerates gastric emptying, giving itraconazole less contact time with the gastric mucosa and slightly reducing absorption
E) Omeprazole chelates the triazole ring of itraconazole in the stomach, reducing free drug concentrations and lowering systemic exposure
ANSWER: A
Rationale:
Option A is correct. Itraconazole capsules contain the drug coated onto sugar spheres; dissolution requires an acidic gastric environment to solubilize the lipophilic compound. When gastric pH is elevated by proton pump inhibitors (PPIs) such as omeprazole, histamine type-2 receptor antagonists (H2RAs), or antacids, capsule dissolution is severely impaired and oral bioavailability falls dramatically, sometimes to near zero. This is a clinically critical interaction. For patients requiring acid suppression, the itraconazole oral solution (which uses hydroxypropyl-beta-cyclodextrin as a solubilizing vehicle and is far less pH-dependent) should be used instead.
Option B: Option B is incorrect; omeprazole does have a clinically meaningful and potentially severe effect on itraconazole capsule absorption, which is well-documented and considered a significant drug-drug interaction.
Option C: Option C is incorrect; omeprazole is not a CYP3A4 inhibitor of clinical significance. It is a CYP2C19 substrate and mild CYP2C19 inhibitor but does not substantially inhibit CYP3A4.
Option D: Option D is incorrect; omeprazole does not meaningfully accelerate gastric emptying, and gastric emptying rate is not the relevant mechanism for itraconazole capsule absorption impairment.
Option E: Option E is incorrect; chelation of the triazole ring by omeprazole in the stomach does not occur; the interaction is entirely pH-mediated through impaired capsule dissolution.
4. Among the first-generation azole antifungals, fluconazole has a pharmacokinetic advantage that makes it the preferred agent for consolidation and long-term suppressive therapy of cryptococcal meningitis. What property accounts for this advantage?
A) Fluconazole is actively transported into the CNS (central nervous system) by P-glycoprotein efflux pumps expressed on the choroid plexus
B) Fluconazole has greater intrinsic antifungal potency against Cryptococcus neoformans than itraconazole, independent of CNS penetration
C) Fluconazole is relatively hydrophilic and minimally protein-bound, allowing it to achieve CSF (cerebrospinal fluid) concentrations that approach 80% of plasma concentrations
D) Fluconazole is converted to an active CNS-penetrant metabolite by hepatic CYP3A4, which accumulates preferentially in brain tissue
E) Fluconazole has a larger volume of distribution than itraconazole, distributing more extensively into brain parenchyma
ANSWER: C
Rationale:
Option C is correct. Fluconazole achieves cerebrospinal fluid (CSF) concentrations of approximately 70 to 90% of simultaneous plasma concentrations, a consequence of its relative hydrophilicity and low protein binding (approximately 11 to 12%). These properties allow fluconazole to cross the blood-brain barrier by passive diffusion far more effectively than itraconazole, which is highly lipophilic and approximately 99.8% protein-bound — properties that paradoxically restrict CNS penetration despite high tissue accumulation elsewhere. This favorable CNS pharmacokinetics makes fluconazole the standard consolidation and maintenance agent for cryptococcal meningitis following amphotericin B induction therapy, typically given at 400 mg daily for consolidation and 200 mg daily for long-term suppression in HIV (human immunodeficiency virus)-associated disease.
Option A: Option A is incorrect; P-glycoprotein is an efflux transporter that pumps drugs out of the CNS, not into it. Fluconazole's CNS penetration results from passive diffusion, not active influx.
Option B: Option B is incorrect; itraconazole has in vitro activity against Cryptococcus, but its poor CSF penetration makes it unsuitable for CNS fungal infections regardless of its potency in other compartments.
Option D: Option D is incorrect; fluconazole is not a prodrug and does not rely on CYP3A4 conversion for CNS-penetrant activity. It is active as the parent compound.
Option E: Option E is incorrect; fluconazole actually has a smaller volume of distribution (approximately 0.7 L/kg) than itraconazole (approximately 11 L/kg). CNS penetration is governed by protein binding and lipophilicity, not volume of distribution per se.
5. In a patient with recurrent oropharyngeal candidiasis who has received prolonged fluconazole therapy, susceptibility testing reveals a Candida albicans isolate with elevated fluconazole minimum inhibitory concentrations (MICs). Sequencing of the ERG11 gene reveals a point mutation at a key residue. How does an ERG11 point mutation cause azole resistance?
A) The ERG11 mutation prevents the fungal cell from synthesizing lanosterol, bypassing the need for CYP51 activity and eliminating the drug target entirely
B) The ERG11 mutation causes overexpression of CDR1 (Candida Drug Resistance 1) and CDR2 (Candida Drug Resistance 2) efflux pumps, reducing intracellular azole concentrations
C) The ERG11 mutation converts CYP51 from a sterol demethylase into a sterol reductase, allowing ergosterol synthesis to proceed via an alternative pathway unaffected by azoles
D) The ERG11 mutation increases CYP51 gene copy number through chromosomal duplication, producing more enzyme than azole molecules can inhibit at therapeutic concentrations
E) The ERG11 mutation alters key amino acid residues in CYP51 that normally contact the azole triazole nitrogen, reducing the binding affinity of azoles for the enzyme active site
ANSWER: E
Rationale:
Option E is correct. ERG11 encodes CYP51 (lanosterol 14-alpha-demethylase), the azole target enzyme. Point mutations at specific amino acid positions alter the three-dimensional structure of the CYP51 active site in ways that reduce contact between the azole triazole nitrogen (which normally coordinates with the heme iron of CYP51) and the surrounding residues. Over 140 distinct ERG11 point mutations have been described in resistant Candida albicans clinical isolates; hot-spot positions include tyrosine-132 (Y132H), lysine-143 (K143R), and phenylalanine-145 (F145L). The result is that the enzyme retains its catalytic function (ergosterol synthesis continues) but has reduced affinity for azole drugs, so higher drug concentrations are required for inhibition — a shift reflected as elevated MICs.
Option A: Option A is incorrect; ERG11 mutations do not eliminate lanosterol synthesis or the CYP51 enzyme itself. The enzyme remains functional; it simply binds azoles with lower affinity.
Option B: Option B is incorrect; CDR1 and CDR2 efflux pump upregulation is a separate and distinct resistance mechanism regulated by the TAC1 transcription factor gene, not by ERG11 mutations.
Option C: Option C is incorrect; CYP51 is not converted to a reductase by ERG11 mutations and no alternative ergosterol pathway bypasses CYP51 in Candida.
Option D: Option D is incorrect; although chromosomal duplication of the region containing ERG11 can contribute to resistance in some isolates, the primary mechanism of ERG11-mediated resistance is reduced binding affinity through point mutation, not gene amplification.
6. A Candida albicans isolate from a patient with HIV (human immunodeficiency virus) and recurrent thrush shows cross-resistance to fluconazole, itraconazole, and voriconazole. Molecular analysis identifies upregulated expression of CDR1 and CDR2 genes driven by a gain-of-function mutation in the TAC1 transcription factor gene. Which mechanism of azole resistance does this represent?
A) Target site alteration — point mutations in ERG11 reduce the binding affinity of all azole class members for the CYP51 active site
B) Drug efflux — overexpression of CDR1 (Candida Drug Resistance 1) and CDR2 (Candida Drug Resistance 2) ATP-binding cassette transporters pumps azoles out of the fungal cell, reducing intracellular drug concentrations
C) Target bypass — ERG3 (C-5 sterol desaturase gene) mutations prevent accumulation of toxic 14-alpha-methylated sterol intermediates, allowing the fungal cell to survive despite CYP51 inhibition
D) Target amplification — duplication of the ERG11 chromosomal locus increases CYP51 enzyme quantity beyond what azole concentrations can fully inhibit
E) Reduced drug uptake — loss-of-function mutations in fungal plasma membrane permeases reduce passive azole diffusion into the fungal cell
ANSWER: B
Rationale:
Option B is correct. CDR1 (Candida Drug Resistance 1) and CDR2 (Candida Drug Resistance 2) are members of the ABC (adenosine triphosphate-binding cassette) transporter superfamily. Their overexpression actively exports azole molecules from the fungal cytoplasm, reducing intracellular drug concentrations below the threshold needed to inhibit CYP51 sufficiently. Because CDR1 and CDR2 transport all azole class members (fluconazole, itraconazole, voriconazole), upregulation confers broad cross-class azole resistance, as seen in this isolate. The TAC1 transcription factor normally regulates CDR1 and CDR2 expression; gain-of-function TAC1 mutations constitutively activate both transporters, producing persistent high-level resistance.
Option A: Option A is incorrect; while ERG11 mutations cause resistance by reducing CYP51 binding affinity, the scenario specifically describes upregulated CDR1 and CDR2 driven by TAC1, which is efflux-mediated resistance, not target site alteration.
Option C: Option C is incorrect; ERG3 mutation-mediated target bypass is a distinct third mechanism that prevents accumulation of toxic sterol intermediates rather than reducing intracellular azole concentration.
Option D: Option D is incorrect; ERG11 locus duplication is a possible contributor to resistance but is not the mechanism described here, where CDR1/CDR2 upregulation is the identified finding.
Option E: Option E is incorrect; reduced passive drug uptake through membrane permease mutations is not a well-established primary resistance mechanism for azoles in Candida, unlike the efflux mechanism described here.
7. A neutropenic patient with acute myeloid leukemia develops candidemia. The blood culture grows Candida krusei. Which statement about antifungal selection for this patient is correct?
A) Candida krusei is intrinsically resistant to fluconazole due to low-affinity CYP51 combined with drug efflux, and fluconazole should never be used regardless of susceptibility testing results
B) Candida krusei is intrinsically resistant to all azoles and all echinocandins, requiring treatment with liposomal amphotericin B as the only effective option
C) Candida krusei susceptibility to fluconazole is variable and must be confirmed by MIC (minimum inhibitory concentration) testing before initiating therapy
D) Candida krusei resistance to fluconazole is acquired through ERG11 mutations during prior azole therapy and is not present in treatment-naive isolates
E) Candida krusei is fluconazole-resistant only at standard doses; doubling the fluconazole dose to 800 mg daily overcomes the resistance mechanism in most clinical isolates
ANSWER: A
Rationale:
Option A is correct. Candida krusei (now reclassified as Pichia kudriavzevii) has intrinsic resistance to fluconazole — a resistance that is present in all isolates regardless of prior antifungal exposure. The mechanism involves a combination of low intrinsic affinity of the CYP51 enzyme for fluconazole and constitutive expression of CDR (Candida Drug Resistance) efflux transporters. Because intrinsic resistance is not acquired, susceptibility testing results for fluconazole in C. krusei should not be used to justify treatment — even an isolate that appears susceptible in vitro by some testing methods should not be treated with fluconazole. Echinocandins are the treatment of choice for invasive C. krusei infections.
Option B: Option B is incorrect; Candida krusei is not intrinsically resistant to echinocandins, which are active and are the preferred treatment. Liposomal amphotericin B is an alternative but not the only option.
Option C: Option C is incorrect; intrinsic fluconazole resistance in C. krusei is class-wide and not isolate-dependent; susceptibility testing for fluconazole does not need to be confirmed because the species-level prediction of resistance is reliable.
Option D: Option D is incorrect; C. krusei resistance to fluconazole is intrinsic and present in all isolates, not acquired through ERG11 mutations during therapy.
Option E: Option E is incorrect; dose escalation does not overcome intrinsic C. krusei resistance. The resistance is mechanistic, not concentration-dependent in the clinical dose range.
8. A patient on stable long-term warfarin anticoagulation for atrial fibrillation is started on fluconazole 200 mg daily for esophageal candidiasis. Five days later, her INR (international normalized ratio) has risen from 2.4 to 6.1. Which mechanism best explains this interaction?
A) Fluconazole displaces warfarin from albumin binding sites, acutely increasing the free (unbound) fraction of warfarin available to exert pharmacodynamic effect
B) Fluconazole induces hepatic CYP2C9 expression, increasing S-warfarin metabolism and paradoxically causing an unpredictable anticoagulant response
C) Fluconazole inhibits vitamin K epoxide reductase in the liver, directly potentiating the anticoagulant effect of warfarin independent of drug metabolism
D) Fluconazole is a potent inhibitor of CYP2C9 (cytochrome P450 2C9), the enzyme primarily responsible for metabolism of S-warfarin, the more pharmacologically active enantiomer, causing reduced S-warfarin clearance and elevated INR
E) Fluconazole inhibits intestinal CYP3A4, increasing absorption of the R-warfarin enantiomer and raising total warfarin plasma concentrations
ANSWER: D
Rationale:
Option D is correct. Fluconazole is a potent inhibitor of CYP2C9 (cytochrome P450 2C9), the primary enzyme responsible for the hydroxylation and clearance of S-warfarin. S-warfarin is the more pharmacologically potent enantiomer of the racemic warfarin mixture, with approximately 3 to 5 times the anticoagulant activity of R-warfarin. Fluconazole inhibition of CYP2C9 reduces S-warfarin clearance, causing plasma S-warfarin concentrations to rise and the INR to increase substantially — typically within 3 to 5 days of starting fluconazole, consistent with this patient's clinical course. INR increases of 2- to 3-fold have been reported. Patients receiving warfarin who are started on fluconazole require INR monitoring within 3 to 5 days with proactive warfarin dose reduction.
Option A: Option A is incorrect; protein binding displacement is a transient phenomenon that rarely causes sustained clinically significant INR elevation; it is not the mechanism of the fluconazole-warfarin interaction.
Option B: Option B is incorrect; fluconazole inhibits CYP2C9, it does not induce it. Induction would increase warfarin metabolism and lower the INR, the opposite of what is observed.
Option C: Option C is incorrect; fluconazole does not inhibit vitamin K epoxide reductase (VKORC1); that is the mechanism of warfarin itself.
Option E: Option E is incorrect; warfarin is not primarily a CYP3A4 substrate for either enantiomer; fluconazole's principal interaction with warfarin is via CYP2C9 inhibition affecting S-warfarin, not through CYP3A4 and R-warfarin.
9. A renal transplant recipient on stable tacrolimus immunosuppression develops histoplasmosis and is started on itraconazole oral solution. Over the following week, the patient develops worsening renal function, tremor, and hypertension. Tacrolimus trough concentrations are found to be markedly elevated. Which mechanism best explains this drug interaction?
A) Itraconazole competes with tacrolimus for renal tubular secretion via OAT (organic anion transporter) pathways, reducing tacrolimus renal clearance and raising trough concentrations
B) Itraconazole inhibits CYP2C19 (cytochrome P450 2C19), the primary enzyme responsible for tacrolimus N-demethylation in the intestinal wall, increasing tacrolimus bioavailability
C) Itraconazole is a potent inhibitor of both CYP3A4 (cytochrome P450 3A4) and P-glycoprotein efflux transport, the two principal determinants of tacrolimus clearance, causing tacrolimus concentrations to rise 5- to 10-fold or more
D) Itraconazole induces tacrolimus redistribution from peripheral tissue compartments into the central blood compartment, transiently raising measured trough concentrations without increasing total body tacrolimus exposure
E) Itraconazole inhibits calcineurin directly, producing synergistic immunosuppression and nephrotoxicity through a mechanism independent of tacrolimus pharmacokinetics
ANSWER: C
Rationale:
Option C is correct. Tacrolimus is a substrate of both CYP3A4 and P-glycoprotein (P-gp), an efflux transporter expressed in the intestinal wall and in hepatocytes. CYP3A4 mediates the majority of tacrolimus metabolism in the gut wall (first-pass) and liver, while P-gp limits intestinal absorption and promotes biliary excretion. Itraconazole potently inhibits both CYP3A4 and P-gp simultaneously, dramatically increasing tacrolimus bioavailability (by inhibiting intestinal P-gp and CYP3A4) and reducing its systemic clearance (by inhibiting hepatic CYP3A4). The combined effect can increase tacrolimus blood concentrations by 5- to 10-fold or more. Tacrolimus has an extremely narrow therapeutic index, and concentration increases of this magnitude cause calcineurin inhibitor toxicity including nephrotoxicity, neurotoxicity (tremor, headache), and hypertension. When itraconazole is initiated in transplant patients on tacrolimus, the tacrolimus dose must be proactively reduced — often by 50 to 75% — and trough concentrations monitored daily until a new steady state is achieved.
Option A: Option A is incorrect; tacrolimus elimination is overwhelmingly metabolic (CYP3A4-dependent), not renal. Renal tubular transporter competition is not the mechanism of this interaction.
Option B: Option B is incorrect; tacrolimus is a CYP3A4 substrate, not a CYP2C19 substrate; itraconazole's clinically significant interactions are mediated through CYP3A4 and P-gp inhibition.
Option D: Option D is incorrect; redistribution from tissue compartments is not a recognized mechanism of the itraconazole-tacrolimus interaction, and this explanation does not account for the toxicity observed.
Option E: Option E is incorrect; itraconazole does not inhibit calcineurin. It is an antifungal agent; its toxicity in this scenario is entirely pharmacokinetically mediated through elevated tacrolimus concentrations.
10. A clinician is selecting between itraconazole capsules and itraconazole oral solution for a patient with chronic pulmonary histoplasmosis who takes pantoprazole (a proton pump inhibitor) and is being treated in the outpatient setting. Which statement correctly distinguishes the two formulations?
A) The oral solution should be taken with a full meal to maximize absorption via bile-stimulated solubilization, while the capsule formulation is absorbed equally well in fasted and fed states
B) The capsule formulation achieves higher peak plasma concentrations than the oral solution because the capsule bypasses first-pass intestinal metabolism by releasing drug directly in the duodenum
C) Both formulations are bioequivalent and interchangeable at the same dose; the choice between them is based solely on patient preference for taste and convenience
D) The oral solution has lower bioavailability than the capsule formulation and is therefore reserved for patients who cannot swallow solid dosage forms
E) The oral solution uses hydroxypropyl-beta-cyclodextrin as a solubilizing vehicle, should be taken on an empty stomach, and achieves more reliable absorption than capsules because its bioavailability is far less dependent on gastric pH
ANSWER: E
Rationale:
Option E is correct. The itraconazole oral solution incorporates hydroxypropyl-beta-cyclodextrin as a solubilizing excipient, which pre-solubilizes the highly lipophilic itraconazole and renders absorption far less dependent on gastric acid and bile than the capsule formulation. The oral solution should be taken on an empty stomach (fasting state), where it achieves bioavailability of approximately 60% with much less interpatient variability than capsules under similar conditions. For this patient on pantoprazole — which raises gastric pH and would dramatically impair capsule dissolution — the oral solution is clearly the preferred formulation. For all systemic fungal infections, the oral solution is generally preferred over capsules because of more reliable and consistent drug exposure.
Option A: Option A is incorrect; the oral solution is taken on an empty stomach (fasting), not with food; it is the capsule formulation that requires food (and acid) for adequate dissolution, not the solution.
Option B: Option B is incorrect; the capsule formulation does not bypass intestinal metabolism and is not absorbed more rapidly or completely than the solution; under optimal conditions the two formulations achieve similar bioavailability, but the solution is more reliable across a range of clinical scenarios.
Option C: Option C is incorrect; the two formulations are not bioequivalent and are not interchangeable at the same dose under all conditions. Their absorption profiles differ substantially with respect to food, gastric pH, and clinical setting.
Option D: Option D is incorrect; the oral solution does not have lower bioavailability than the capsule. Under typical clinical conditions — particularly in patients on acid-suppressing therapy — the oral solution reliably achieves higher and more consistent plasma concentrations than the capsule formulation.
11. A 68-year-old man with ischemic cardiomyopathy and an ejection fraction of 30% develops onychomycosis. His dermatologist considers itraconazole pulse therapy. Which cardiac concern specific to itraconazole is most relevant to this prescribing decision?
A) Itraconazole causes dose-dependent QTc (corrected QT interval) prolongation through direct hERG (human ether-a-go-go-related gene) channel blockade, posing a risk of torsades de pointes in patients with reduced ejection fraction
B) Itraconazole exerts a negative inotropic effect on the myocardium and is contraindicated in patients with evidence of ventricular dysfunction, making it inappropriate for this patient regardless of onychomycosis severity
C) Itraconazole inhibits CYP3A4 and substantially increases plasma concentrations of common heart failure medications including digoxin, loop diuretics, and beta-blockers, requiring dose adjustments for all co-administered agents
D) Itraconazole causes direct myocardial inflammation through a hypersensitivity mechanism, with the risk being highest in patients with pre-existing structural heart disease
E) Itraconazole prolongs the PR interval by blocking L-type calcium channels in AV (atrioventricular) nodal tissue, causing clinically significant bradycardia in patients with reduced cardiac output
ANSWER: B
Rationale:
Option B is correct. Itraconazole has a well-documented negative inotropic effect on the myocardium — it reduces cardiac contractility — and this has caused or worsened congestive heart failure in patients receiving the drug. The FDA labeling for itraconazole includes a contraindication for its use in patients with evidence of ventricular dysfunction, including congestive heart failure or a history of congestive heart failure. For a patient with ischemic cardiomyopathy and an ejection fraction of 30%, itraconazole is formally contraindicated. Terbinafine is generally preferred for onychomycosis in patients with cardiac dysfunction.
Option A: Option A is incorrect; while fluconazole causes clinically significant QTc prolongation through direct hERG channel blockade, this description applies primarily to fluconazole rather than to itraconazole's principal cardiac concern. Itraconazole does have some QTc-prolonging potential (partly indirect, via CYP3A4 inhibition increasing levels of co-administered QT-prolonging drugs), but the primary itraconazole-specific cardiac contraindication is the negative inotropic effect and heart failure risk, not hERG blockade.
Option C: Option C is incorrect; while itraconazole does inhibit CYP3A4 and can increase concentrations of some co-administered drugs, loop diuretics and beta-blockers are not primarily CYP3A4 substrates. Digoxin is a P-glycoprotein substrate whose levels can be elevated by itraconazole, but this is not the principal cardiac contraindication driving the prescribing decision here.
Option D: Option D is incorrect; itraconazole does not cause direct myocardial inflammation through a hypersensitivity mechanism. Its cardiac toxicity is pharmacodynamic (negative inotropy), not immunologically mediated.
Option E: Option E is incorrect; itraconazole is not a clinically significant blocker of L-type calcium channels in AV nodal tissue and does not cause bradycardia through that mechanism.
12. A patient receiving fluconazole 400 mg daily for cryptococcal meningitis consolidation is found to have a QTc (corrected QT interval) of 510 ms on routine ECG (electrocardiogram). She also takes methadone for opioid use disorder. Which mechanism explains fluconazole's direct contribution to QTc prolongation?
A) Fluconazole directly blocks the hERG (human ether-a-go-go-related gene) cardiac potassium channel, which conducts the rapid delayed rectifier potassium current (IKr) responsible for ventricular repolarization, causing dose-dependent QTc prolongation
B) Fluconazole inhibits cardiac CYP2D6 (cytochrome P450 2D6) within cardiomyocytes, reducing local metabolism of endogenous catecholamines and prolonging action potential duration
C) Fluconazole competitively antagonizes the adenosine A1 receptor in the sinoatrial node, slowing heart rate and secondarily prolonging the QT interval at lower heart rates
D) Fluconazole chelates magnesium ions in the myocardium, functionally reducing intracellular magnesium concentrations and destabilizing cardiac repolarization
E) Fluconazole activates the L-type calcium channel in ventricular cardiomyocytes, prolonging the plateau phase of the cardiac action potential and extending repolarization duration
ANSWER: A
Rationale:
Option A is correct. Fluconazole directly blocks the hERG (human ether-a-go-go-related gene) potassium channel, which underlies the rapid delayed rectifier potassium current (IKr) in ventricular cardiomyocytes. IKr is a major repolarizing current during phase 3 of the cardiac action potential; its inhibition slows repolarization, prolongs the QTc interval, and increases the risk of early afterdepolarizations and torsades de pointes (TdP), a potentially fatal polymorphic ventricular tachycardia. The risk with fluconazole is dose-dependent and is highest at doses of 400 mg or above, in patients with additional QTc risk factors (hypokalemia, hypomagnesemia, female sex, bradycardia, structural heart disease), and when combined with other QT-prolonging drugs such as methadone. Methadone is itself a potent hERG channel blocker, making the combination particularly hazardous. Baseline and follow-up ECG monitoring is essential in this clinical scenario.
Option B: Option B is incorrect; fluconazole does not inhibit cardiac CYP2D6 within cardiomyocytes. CYP2D6 does not play a role in cardiac action potential duration; fluconazole's cardiac effect is direct channel blockade at the hERG level.
Option C: Option C is incorrect; fluconazole does not antagonize adenosine A1 receptors. This is not a mechanism of QTc prolongation for any clinical azole antifungal.
Option D: Option D is incorrect; magnesium chelation is not a pharmacological mechanism of fluconazole. Hypomagnesemia (from other causes) is a risk factor that augments QTc prolongation, but fluconazole does not chelate myocardial magnesium.
Option E: Option E is incorrect; L-type calcium channel activation would prolong the action potential plateau phase, but this is not fluconazole's mechanism. Fluconazole acts on the hERG potassium channel during repolarization, not on L-type calcium channels.
13. A Candida albicans isolate shows high-level azole resistance in combination with reduced susceptibility to amphotericin B. Genetic analysis identifies a loss-of-function mutation in the ERG3 gene encoding C-5 sterol desaturase. Which mechanism of azole resistance does this ERG3 mutation confer?
A) ERG3 mutation upregulates expression of CYP51 (lanosterol 14-alpha-demethylase), providing more enzyme than azoles can inhibit at clinically achievable concentrations
B) ERG3 mutation prevents lanosterol synthesis by blocking the squalene epoxidase reaction, eliminating the substrate for CYP51 and making azole inhibition pharmacologically irrelevant
C) ERG3 mutation causes constitutive activation of the TAC1 transcription factor, driving overexpression of CDR1 and CDR2 efflux transporters and pumping azoles out of the cell
D) ERG3 mutation prevents conversion of 14-alpha-methylfecosterol to toxic methylated sterol intermediates; since toxic sterol accumulation normally contributes to the antifungal effect of azoles, its prevention allows the fungal cell to survive despite CYP51 inhibition
E) ERG3 mutation increases the structural rigidity of the fungal cell membrane by incorporating alternative sterols, physically blocking azole molecules from reaching the CYP51 active site in the endoplasmic reticulum
ANSWER: D
Rationale:
Option D is correct. Under normal circumstances, azole inhibition of CYP51 causes accumulation of 14-alpha-methylfecosterol, which is then converted by C-5 sterol desaturase (ERG3) to more toxic methylated sterol intermediates including 14-alpha-methyl-3,6-diol. These toxic intermediates disrupt membrane function and contribute to the fungicidal or fungistatic effect of azoles. ERG3 (C-5 sterol desaturase gene) loss-of-function mutations block the conversion of 14-alpha-methylfecosterol to these toxic downstream products, preventing the accumulation of membrane-damaging intermediates. The fungal cell can then survive CYP51 inhibition because the toxic consequences of upstream sterol pathway blockade are eliminated. This is called target bypass because the cell circumvents the toxic effects of azole action rather than preventing drug binding. ERG3 mutations also reduce ergosterol content in the membrane, which contributes to the observed cross-resistance with amphotericin B (which binds ergosterol).
Option A: Option A is incorrect; ERG3 mutations do not upregulate CYP51 expression. Increased CYP51 quantity from ERG11 locus duplication is a distinct (and less common) mechanism, not related to ERG3.
Option B: Option B is incorrect; ERG3 is positioned downstream of CYP51 in the ergosterol pathway, not at the squalene epoxidase step. ERG3 mutations do not affect lanosterol synthesis and do not eliminate the CYP51 substrate.
Option C: Option C is incorrect; CDR1 and CDR2 efflux upregulation is regulated by the TAC1 transcription factor, not ERG3. ERG3 mutations cause resistance through sterol pathway bypass, not through efflux transporter activation.
Option E: Option E is incorrect; ERG3 mutations do not physically block azole access to CYP51. The resistance mechanism is metabolic (prevention of toxic intermediate accumulation), not physical exclusion of drug from the target enzyme.
14. A patient with disseminated histoplasmosis is being treated with itraconazole oral solution 200 mg twice daily. Fourteen days into therapy, a plasma trough concentration is measured. Which statement correctly describes the target and rationale for therapeutic drug monitoring (TDM) with itraconazole?
A) The target itraconazole trough concentration for treatment of invasive fungal infection is above 0.1 mcg/mL; levels above 2.0 mcg/mL are considered toxic and require dose reduction
B) TDM is not routinely recommended for itraconazole because its predictable first-order pharmacokinetics and consistent oral bioavailability make plasma concentration monitoring unnecessary
C) The recommended itraconazole trough target for treatment of invasive fungal infections is above 1.0 mcg/mL; both itraconazole and its active metabolite hydroxy-itraconazole are measured together and high interpatient pharmacokinetic variability makes TDM essential
D) The itraconazole trough should be drawn at 24 hours after the loading dose on day 1 of therapy, before steady state is reached, to confirm adequate early drug exposure and guide dosing adjustments
E) TDM for itraconazole measures only the parent compound and excludes hydroxy-itraconazole because the metabolite has no antifungal activity and contributes to toxicity rather than efficacy
ANSWER: C
Rationale:
Option C is correct. TDM is routinely recommended for itraconazole therapy of invasive fungal infections because of high interpatient variability in itraconazole pharmacokinetics driven by CYP3A4 genetic polymorphism, variable food and gastric pH effects on absorption, and the significant impact of drug interactions on itraconazole levels. The target trough concentration for treatment of invasive fungal infections is above 1.0 mcg/mL (for prophylaxis, the target is above 0.5 mcg/mL). Standard assays measure combined plasma concentrations of itraconazole and its principal active metabolite hydroxy-itraconazole, which has antifungal activity comparable to the parent compound. Trough concentrations are measured at steady state, typically after 14 days of therapy, which is the appropriate timing in this case. Levels above 10 mcg/mL are associated with increased toxicity.
Option A: Option A is incorrect; the TDM target for treatment is above 1.0 mcg/mL, not above 0.1 mcg/mL, which would be subtherapeutic. The upper toxicity threshold is approximately 10 mcg/mL, not 2.0 mcg/mL.
Option B: Option B is incorrect; TDM is specifically recommended for itraconazole precisely because its pharmacokinetics are not predictable — high interpatient variability in absorption, distribution, and CYP3A4-mediated metabolism means that a standard dose does not reliably produce therapeutic concentrations in all patients.
Option D: Option D is incorrect; trough concentrations drawn on day 1 before steady state is reached are not interpretable for dosing decisions because itraconazole has a long half-life (24 to 42 hours) and requires approximately 14 days to reach steady state. Day 1 levels would substantially underestimate the eventual steady-state exposure.
Option E: Option E is incorrect; standard itraconazole TDM assays measure both itraconazole and hydroxy-itraconazole together because hydroxy-itraconazole is pharmacologically active with antifungal potency comparable to the parent compound. Excluding it would underestimate total antifungal drug exposure.
15. A hospitalized patient develops candidemia. Blood cultures grow Candida glabrata (now reclassified as Nakaseomyces glabratae). The clinical team asks whether fluconazole can be used. Which statement best reflects the prescribing framework for fluconazole against Candida glabrata?
A) Candida glabrata is uniformly susceptible to fluconazole; resistance has not been documented and fluconazole is the first-line agent for C. glabrata candidemia
B) Candida glabrata is uniformly resistant to fluconazole and to all azoles; echinocandin therapy is mandatory in all cases regardless of susceptibility testing
C) Fluconazole resistance in Candida glabrata is always acquired during therapy and is never present at baseline in treatment-naive patients; fluconazole is safe as initial empirical therapy
D) Fluconazole susceptibility in Candida glabrata depends on the route of infection; bloodstream isolates are universally resistant while mucosal isolates retain susceptibility
E) Candida glabrata has the highest azole resistance rates among common Candida species, with fluconazole resistance rates of 10 to 30% in many centers; echinocandin is preferred for invasive infections, with fluconazole considered only if confirmed susceptible and the patient is clinically stable
ANSWER: E
Rationale:
Option E is correct. Candida glabrata has the highest azole resistance rates among the common Candida species causing bloodstream infections, driven primarily by CDR1 and CDR2 efflux pump upregulation and secondarily by ERG11 mutations. Fluconazole resistance rates of 10 to 30% are reported in many centers, and an even larger proportion of isolates have susceptibility-dose-dependent (SDD) profiles requiring high fluconazole doses that approach toxic concentrations. Because empirical azole therapy risks treatment failure for the substantial proportion of resistant isolates, current Infectious Diseases Society of America (IDSA) guidelines recommend echinocandins as first-line therapy for C. glabrata candidemia. Fluconazole may be considered for step-down only in a clinically stable patient with confirmed fluconazole-susceptible isolates and negative follow-up blood cultures.
Option A: Option A is incorrect; Candida glabrata does not have uniform fluconazole susceptibility — it has the highest azole resistance rates of any common Candida species and is not considered appropriate for empirical fluconazole therapy.
Option B: Option B is incorrect; Candida glabrata is not uniformly resistant to all azoles (voriconazole and posaconazole retain activity in many isolates), and echinocandin therapy, while preferred, is not universally mandatory for every case if susceptibility is confirmed.
Option C: Option C is incorrect; fluconazole resistance in C. glabrata is frequently present at baseline (de novo) due to constitutive efflux mechanisms, not exclusively acquired during therapy. Using fluconazole empirically for C. glabrata candidemia is therefore risky.
Option D: Option D is incorrect; fluconazole resistance in C. glabrata does not segregate by infection site in this way. Bloodstream isolates are not uniformly resistant, and mucosal isolates do not retain uniform susceptibility; resistance is species-level and applies regardless of infection site.
16. Itraconazole has an extraordinarily large volume of distribution (Vd) of approximately 11 L/kg, reflecting massive tissue accumulation. Which of the following clinical observations is a direct consequence of this pharmacokinetic property?
A) Despite very high concentrations in skin, nails, lungs, and liver, itraconazole achieves poor CSF (cerebrospinal fluid) and aqueous humor concentrations and cannot be used for CNS (central nervous system) fungal infections
B) The large volume of distribution means itraconazole is renally cleared rather than hepatically metabolized, because extensive tissue binding reduces hepatic extraction
C) The large volume of distribution causes itraconazole to displace co-administered drugs from tissue protein-binding sites, increasing the free plasma concentrations of agents such as tacrolimus and cyclosporine
D) The large volume of distribution produces a very short terminal elimination half-life because the drug leaves the central compartment rapidly and is cleared from tissue before returning to plasma
E) The large volume of distribution allows itraconazole to achieve CNS concentrations exceeding plasma concentrations, making it particularly effective for treatment of cryptococcal meningitis compared with fluconazole
ANSWER: A
Rationale:
Option A is correct. Although itraconazole distributes extensively into highly lipophilic tissues including skin, nails, lungs, liver, and adipose tissue — with tissue concentrations exceeding plasma concentrations by factors of 10 to 100 — it does not penetrate well into the CNS or CSF. This apparent paradox is explained by the fact that itraconazole's high lipophilicity and extensive plasma protein binding (approximately 99.8% protein-bound) actually restrict its entry into the aqueous CSF compartment. Drug distribution across the blood-brain barrier into CSF is governed by the free (unbound) drug fraction; with protein binding of 99.8%, the free fraction available to cross into CSF is extremely small. By contrast, fluconazole, which is far less lipophilic and only approximately 11 to 12% protein-bound, achieves CSF concentrations approaching 80 to 90% of plasma concentrations. This pharmacokinetic distinction makes itraconazole unsuitable for CNS fungal infections, despite its superior tissue penetration at other sites.
Option B: Option B is incorrect; itraconazole is extensively metabolized by hepatic CYP3A4, not renally cleared. Extensive tissue distribution does not redirect elimination to the kidney.
Option C: Option C is incorrect; itraconazole displacing co-administered drugs from tissue protein-binding sites is not the mechanism of its interaction with tacrolimus and cyclosporine; those interactions are mediated through CYP3A4 and P-glycoprotein inhibition, not protein binding displacement.
Option D: Option D is incorrect; the large volume of distribution produces a prolonged, not shortened, terminal half-life, because drug must be released slowly from tissue compartments back into the central circulation before elimination can occur. Itraconazole has a terminal half-life of 24 to 42 hours that extends with prolonged use.
Option E: Option E is incorrect; the properties described are the opposite of itraconazole's actual CNS penetration profile. Itraconazole achieves poor CSF concentrations and is not appropriate for cryptococcal meningitis. Fluconazole, not itraconazole, is preferred for CNS cryptococcal disease.
17. Understanding why azoles preferentially affect fungi rather than human cells requires connecting the drug target to the biological difference between fungal and mammalian cell membranes. Which statement best explains the basis for azole selectivity?
A) Human cells lack the CYP51 enzyme entirely; cholesterol biosynthesis in human hepatocytes is CYP51-independent, so human cells are unaffected by azole CYP51 inhibition at any concentration
B) Azoles are selectively concentrated in fungal cells by an active uptake transporter that is absent from mammalian cells, ensuring that the drug only reaches inhibitory concentrations within the fungal cytoplasm
C) Azoles inhibit only fungal CYP51 because the fungal enzyme has a unique triazole-binding pocket that differs structurally from all mammalian CYP450 enzymes, providing absolute enzymatic selectivity
D) Azoles target CYP51-mediated ergosterol synthesis, depleting ergosterol and disrupting fungal membrane integrity and function; mammalian cells synthesize cholesterol rather than ergosterol and their CYP51 is far less sensitive to azoles at therapeutic concentrations, providing a clinically exploitable selectivity window
E) Azoles are selectively toxic to fungi because fungal cell walls contain chitin and beta-glucan that trap the drug at high local concentrations near the cell membrane target, while mammalian cells lack a cell wall and cannot accumulate azoles in the same way
ANSWER: D
Rationale:
Option D is correct. The pharmacological basis for azole selectivity is the difference between the primary membrane sterols of fungi (ergosterol) and mammals (cholesterol), combined with the substantially lower sensitivity of mammalian CYP51 to azoles at therapeutic concentrations. Fungal CYP51 (encoded by ERG11) is responsible for ergosterol synthesis, which is essential for fungal membrane fluidity, permeability, and the function of membrane-embedded proteins and enzymes. Azole inhibition of fungal CYP51 depletes ergosterol and causes accumulation of toxic 14-alpha-methylated sterol intermediates, disrupting fungal membrane integrity. Human cells do contain CYP51 (which participates in cholesterol synthesis via the lanosterol pathway), but mammalian CYP51 has lower inherent sensitivity to azoles at clinically achievable drug concentrations, and cholesterol synthesis in human cells continues via alternative pathways. This differential sensitivity creates the therapeutic window that makes azoles useful antifungals.
Option A: Option A is incorrect; human cells do possess CYP51, which participates in the lanosterol-to-cholesterol biosynthesis pathway. Azoles can affect mammalian CYP51 at supratherapeutic concentrations; selectivity is based on differential sensitivity, not complete absence of the target in human cells.
Option B: Option B is incorrect; selective fungal active uptake of azoles is not the basis of their selectivity. Azoles enter both fungal and mammalian cells by passive diffusion; selectivity arises from the differential importance of CYP51 activity in fungal versus mammalian cells.
Option C: Option C is incorrect; while there are structural differences between fungal and mammalian CYP51 enzymes that contribute to selectivity, azoles are not absolutely selective — they can inhibit mammalian CYP51 and other CYP enzymes at higher concentrations, which contributes to their drug interaction profile. Absolute enzymatic selectivity is overstated.
Option E: Option E is incorrect; the cell wall trapping mechanism is not the basis for azole selectivity. Echinocandins target the cell wall, not azoles; azole selectivity is membrane sterol-based, not related to drug accumulation via the cell wall.
18. A patient being treated for pulmonary tuberculosis with a rifampin (rifampicin)-containing regimen develops histoplasmosis. The team considers adding itraconazole. Which statement correctly describes the pharmacokinetic consequence of this combination?
A) Rifampin inhibits P-glycoprotein in the intestinal wall, dramatically increasing itraconazole bioavailability and raising plasma concentrations to potentially toxic levels
B) Rifampin is a potent inducer of CYP3A4 (cytochrome P450 3A4), the primary enzyme responsible for itraconazole metabolism; co-administration dramatically reduces itraconazole plasma concentrations, often to subtherapeutic levels, making the combination essentially contraindicated
C) Rifampin competitively inhibits itraconazole binding to CYP51 at the antifungal target site, reducing itraconazole's efficacy without affecting its plasma concentration
D) Rifampin and itraconazole mutually inhibit each other's CYP3A4-mediated metabolism, causing both drugs to accumulate to toxic concentrations when co-administered
E) Rifampin displaces itraconazole from plasma protein binding sites, increasing the free fraction of itraconazole transiently but producing a compensatory increase in renal clearance that normalizes total plasma exposure within 48 hours
ANSWER: B
Rationale:
Option B is correct. Rifampin (rifampicin) is one of the most potent inducers of CYP3A4 known in clinical pharmacology, acting via activation of the pregnane X receptor (PXR) to upregulate CYP3A4 gene expression in the intestinal wall and liver. Itraconazole is primarily metabolized by CYP3A4; when rifampin dramatically increases CYP3A4 activity, itraconazole metabolism is accelerated to such a degree that plasma itraconazole concentrations fall to near-zero subtherapeutic levels — sometimes rendering the antifungal treatment essentially ineffective. This combination is considered essentially contraindicated. If both tuberculosis and histoplasmosis require simultaneous treatment, a rifampin-sparing tuberculosis regimen or an alternative antifungal class (such as amphotericin B for induction in severe cases) should be considered.
Option A: Option A is incorrect; rifampin is an inducer of P-glycoprotein, not an inhibitor. Induction of P-gp would further reduce itraconazole absorption and bioavailability by enhancing efflux from enterocytes, compounding the CYP3A4 induction effect and making concentrations even lower, not higher.
Option C: Option C is incorrect; rifampin does not competitively inhibit itraconazole at the CYP51 antifungal target site. Rifampin has no direct antifungal activity. The interaction is entirely pharmacokinetic (CYP3A4 induction reducing itraconazole plasma levels), not pharmacodynamic.
Option D: Option D is incorrect; rifampin is a CYP3A4 inducer, not an inhibitor. It does not inhibit itraconazole metabolism; it accelerates it. The interaction is one-directional — rifampin lowers itraconazole levels, not the reverse.
Option E: Option E is incorrect; rifampin does not significantly displace itraconazole from plasma protein binding sites in a clinically meaningful way, and increased renal clearance is not the mechanism by which rifampin affects itraconazole concentrations. Itraconazole is minimally renally cleared; its elimination is hepatic CYP3A4-dependent.
19. A patient with disseminated coccidioidomycosis and meningeal involvement requires long-term suppressive antifungal therapy. Connecting the clinical requirement for CNS penetration to the pharmacokinetic profiles covered in this module, which agent is the preferred long-term suppressive therapy for coccidioidal meningitis?
A) Itraconazole oral solution 200 mg twice daily, because its broad antifungal spectrum covering endemic mycoses and extensive tissue accumulation make it the first-line agent for all disseminated coccidioidomycosis including meningeal disease
B) Amphotericin B deoxycholate administered by intrathecal or intraventricular route, because systemic azoles do not achieve therapeutic CSF (cerebrospinal fluid) concentrations for coccidioidal meningitis
C) Voriconazole, because it has superior CNS penetration compared to fluconazole and a broader spectrum of activity against Coccidioides species than any first-generation azole
D) Echinocandin (caspofungin or micafungin) administered intravenously, because Coccidioides species have innate azole resistance and respond only to cell wall-active agents
E) Fluconazole 400 mg daily (or higher) as the preferred long-term suppressive agent for coccidioidal meningitis, because its high CSF penetration — approaching 80 to 90% of simultaneous plasma concentrations — is the pharmacokinetic property that makes it suitable for CNS fungal infection while itraconazole is excluded by its poor CSF penetration
ANSWER: E
Rationale:
Option E is correct. Fluconazole is the preferred agent for long-term suppressive therapy of coccidioidal meningitis, at doses of 400 mg daily or higher, with some guidelines recommending 800 mg daily for meningeal disease given its severity. The pharmacokinetic rationale connects directly to material established earlier in this question set: fluconazole's relative hydrophilicity and low protein binding (approximately 11 to 12%) allow it to achieve CSF concentrations of 70 to 90% of plasma concentrations, making it uniquely suited among the first-generation azoles for CNS fungal infections. Itraconazole, despite its broad spectrum that includes Coccidioides, achieves inadequate CSF concentrations due to its high lipophilicity and near-complete protein binding, making it unsuitable for meningeal disease. Coccidioidomycosis requires lifelong azole suppression in patients with meningeal involvement.
Option A: Option A is incorrect; itraconazole is excluded from coccidioidal meningitis treatment precisely because of its poor CNS penetration, which this question set has established as a pharmacokinetic consequence of high protein binding and lipophilicity.
Option B: Option B is incorrect; while intrathecal amphotericin B has been used historically as salvage therapy for refractory coccidioidal meningitis, systemic azoles — particularly fluconazole — do achieve therapeutic CSF concentrations. Intrathecal amphotericin is not first-line and is reserved for azole-refractory disease.
Option C: Option C is incorrect; while voriconazole does achieve good CNS penetration and has activity against Coccidioides, fluconazole remains the standard of care for long-term suppressive therapy of coccidioidal meningitis in current guidelines. Voriconazole may be used in refractory cases.
Option D: Option D is incorrect; echinocandins have no activity against Coccidioides species and no role in the treatment of coccidioidomycosis. Coccidioides species are intrinsically resistant to all echinocandins.
20. Applying the pharmacokinetic principles covered in this module, a clinician is selecting the itraconazole formulation for a hospitalized patient with blastomycosis who is clinically stable and able to take oral medications. The patient is fasting overnight for a procedure and currently takes no acid-suppressing medications. Which formulation decision and administration instruction is most consistent with optimal itraconazole pharmacokinetics?
A) Prescribe itraconazole capsules, instruct the patient to take them on an empty stomach at least one hour before breakfast, because itraconazole capsules require fasting for optimal absorption
B) Prescribe itraconazole capsules, instruct the patient to take them with a full meal and an acidic beverage such as cola, because capsule absorption requires food and gastric acid
C) Prescribe itraconazole oral solution for systemic infection because it provides more reliable bioavailability than capsules; instruct the patient to take it on an empty stomach (fasting) for optimal absorption
D) Either formulation is equivalent for systemic infection; the oral solution is prescribed only when the patient cannot swallow capsules, not as the preferred formulation for treatment of invasive disease
E) Prescribe itraconazole capsules because the oral solution's cyclodextrin vehicle accumulates in renal tissue and is contraindicated in all hospitalized patients who may require IV contrast administration
ANSWER: C
Rationale:
Option C is correct. Itraconazole oral solution is the preferred oral formulation for systemic fungal infections, including blastomycosis, because it achieves more reliable and consistent bioavailability than the capsule formulation. The oral solution uses hydroxypropyl-beta-cyclodextrin as a solubilizing vehicle, which renders absorption far less dependent on gastric acid and bile than capsule dissolution. The oral solution is taken on an empty stomach (fasting state) to maximize absorption — the opposite of the capsule formulation, which requires food. This distinction (capsules with food, solution fasting) is a clinically important detail that is frequently confused and can lead to subtherapeutic drug exposure if reversed. Therapeutic drug monitoring (TDM) should be performed at steady state regardless of formulation.
Option A: Option A is incorrect; itraconazole capsules should be taken with a full meal, not on an empty stomach. Taking capsules while fasting reduces absorption because dissolution requires the acid and bile that food intake stimulates.
Option B: Option B is incorrect; while it is true that capsules require food and acid for absorption, the oral solution is the preferred formulation for systemic infections — not capsules with an acidic beverage. Using an acidic beverage to improve capsule absorption is a practical workaround for patients on acid suppression, not the preferred strategy when the oral solution is available.
Option D: Option D is incorrect; the oral solution is not reserved only for patients who cannot swallow capsules. It is the preferred formulation for systemic infections based on more reliable pharmacokinetics, and capsule use is the fallback, not the default.
Option E: Option E is incorrect; while the cyclodextrin vehicle in the IV itraconazole formulation does accumulate in renal failure (requiring caution if CrCl is below 30 mL/min for the IV form), the oral solution's cyclodextrin is largely not absorbed systemically and does not pose a generalized contraindication in hospitalized patients. This option conflates IV and oral solution cyclodextrin concerns.
21. A critically ill patient in the ICU (intensive care unit) develops candidemia. Blood cultures grow Candida auris, a globally emerging multidrug-resistant pathogen. How does C. auris resistance differ from the resistance patterns of the Candida species covered in this module?
A) Candida auris frequently displays pan-azole resistance — resistance to fluconazole, itraconazole, voriconazole, and posaconazole simultaneously — making echinocandins the drug of choice, with susceptibility testing mandatory because amphotericin B resistance also occurs in some isolates
B) Candida auris resistance is limited to fluconazole alone, identical to the intrinsic resistance pattern of Candida krusei, and voriconazole or itraconazole are reliable alternatives without susceptibility testing
C) Candida auris is resistant only to polyenes (amphotericin B) and retains full susceptibility to all azoles and echinocandins; antifungal selection follows the same framework as Candida albicans
D) Candida auris resistance to azoles is acquired during therapy in the same manner as Candida glabrata and can be reversed by temporarily discontinuing antifungal pressure and then retreating with the same azole
E) Candida auris resistance is limited to echinocandins, making azoles the only reliable treatment option, and susceptibility testing for azoles is therefore not required before initiating fluconazole
ANSWER: A
Rationale:
Option A is correct. Candida auris is a globally emerging pathogen first described in 2009 that has spread rapidly in healthcare settings, particularly ICUs. Unlike the other Candida species covered in this module, C. auris frequently exhibits pan-azole resistance — simultaneous resistance to fluconazole, itraconazole, voriconazole, and posaconazole — often present from the first clinical isolation without prior antifungal exposure. The mechanisms include ERG11 mutations and efflux pump upregulation, similar to other Candida species, but the combination of simultaneous multi-azole resistance at baseline distinguishes C. auris from C. glabrata (where resistance rates are high but not universal) and C. krusei (where only fluconazole intrinsic resistance is consistent). Echinocandins are the preferred empirical treatment for C. auris candidemia, but echinocandin resistance has also been reported and is increasing; amphotericin B resistance occurs in some isolates as well, making susceptibility testing mandatory for all C. auris isolates.
Option B: Option B is incorrect; C. auris resistance is not limited to fluconazole alone and is not analogous to C. krusei's pattern. C. auris exhibits multi-azole resistance across the class, making voriconazole and itraconazole unreliable without susceptibility confirmation.
Option C: Option C is incorrect; C. auris is not resistant only to polyenes. Its primary resistance pattern is pan-azole resistance; polyene resistance is also possible but in a subset of isolates. C. auris cannot be treated like C. albicans.
Option D: Option D is incorrect; C. auris pan-azole resistance is not acquired during therapy in the same way as C. glabrata resistance and cannot be reversed by a treatment break. The resistance is frequently present at baseline and often involves multiple simultaneous mechanisms.
Option E: Option E is incorrect; echinocandin resistance does occur in C. auris but is not the defining characteristic of this pathogen's resistance profile. Azole resistance, not echinocandin resistance, is the dominant and most consistent feature of C. auris.
22. A Candida albicans isolate from a patient with recurrent vulvovaginal candidiasis shows elevated fluconazole MICs (minimum inhibitory concentrations) but retained susceptibility to voriconazole and itraconazole. Molecular analysis identifies upregulation of the MDR1 gene encoding the Mdr1p transporter, driven by a gain-of-function mutation in the MRR1 transcription factor gene. How does this resistance profile differ from CDR1/CDR2-mediated resistance?
A) Mdr1p upregulation causes pan-azole resistance identical to CDR1/CDR2 overexpression because both transporter families pump all azole class members with equal efficiency
B) Mdr1p is a member of the ABC (adenosine triphosphate-binding cassette) superfamily like CDR1 and CDR2, but is expressed only transiently during fluconazole exposure; CDR1/CDR2 expression is constitutive and therefore more clinically durable
C) Mdr1p upregulation causes resistance to all azoles and also to echinocandins, while CDR1/CDR2 upregulation is limited to azoles only; this explains why the isolate shows voriconazole susceptibility despite high fluconazole MICs
D) Mdr1p is a member of the MFS (major facilitator superfamily) of transporters and confers fluconazole-specific resistance without consistently affecting voriconazole or itraconazole susceptibility, distinguishing it from CDR1/CDR2 upregulation which produces cross-resistance to the entire azole class
E) Mdr1p provides fluconazole resistance by sequestering the drug in vacuolar compartments within the fungal cell rather than exporting it across the plasma membrane, a mechanism that CDR1 and CDR2 cannot perform
ANSWER: D
Rationale:
Option D is correct. The MDR1 gene encodes Mdr1p, a member of the major facilitator superfamily (MFS) of drug transporters — a structurally and mechanistically distinct family from the ABC (adenosine triphosphate-binding cassette) transporters CDR1 and CDR2. MFS transporters use the proton motive force (chemiosmotic gradient) rather than ATP hydrolysis for energy. Critically, Mdr1p overexpression confers fluconazole-specific resistance without consistently affecting susceptibility to voriconazole or itraconazole, because Mdr1p's substrate specificity within the azole class favors fluconazole. This explains the clinical isolate in the question: fluconazole resistance with preserved voriconazole and itraconazole susceptibility points toward Mdr1p upregulation rather than CDR1/CDR2. By contrast, CDR1 and CDR2 overexpression produces cross-resistance to fluconazole, itraconazole, and voriconazole — the entire azole class — because these ABC transporters export multiple azole substrates. The MRR1 transcription factor regulates MDR1 expression; gain-of-function MRR1 mutations constitutively activate MDR1, producing stable fluconazole-specific resistance.
Option A: Option A is incorrect; Mdr1p and CDR1/CDR2 do not produce identical resistance profiles. The defining difference is that CDR1/CDR2 produces pan-azole cross-resistance while Mdr1p produces predominantly fluconazole-specific resistance.
Option B: Option B is incorrect; Mdr1p is not an ABC transporter — it is an MFS transporter with a distinct structure and energy source. The characterization of Mdr1p as transient versus CDR1/CDR2 as constitutive is also inaccurate; constitutive MDR1 expression driven by gain-of-function MRR1 mutations is a stable, heritable resistance mechanism.
Option C: Option C is incorrect; Mdr1p does not confer echinocandin resistance; echinocandin resistance in Candida is mediated by FKS1/FKS2 gene mutations affecting beta-1,3-glucan synthase, not by drug efflux transporters.
Option E: Option E is incorrect; Mdr1p is a plasma membrane efflux transporter that exports fluconazole across the plasma membrane to the extracellular space. It does not sequester drug in vacuolar compartments; vacuolar drug sequestration has been proposed for some compounds but is not the established mechanism of Mdr1p-mediated azole resistance.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.